Pintadit P, Isarangkura P B, Chalermchandra K, Pongcharoen S, Sasanakul W, Chulajata R, Green G M
J Med Assoc Thai. 1989 Jan;72 Suppl 1:125-9.
This paper evaluated the effect of VKP in the neonates by oral route with different dosages compared to the standard parenteral route giving a single dose at birth. Two hundred and thirty-six healthy, breast-fed infants were divided into 4 groups receiving vitamin K1 1 mg intramuscularly and 2, 3, 5 mg orally during 2-4 hours after birth. The vitamin K dependent clotting factors were measured by the thrombotest at the age of 2 weeks and 4-6 weeks. The result showed no statistical differences among these 4 groups regarding the mean prothrombin complex level and the number of PC deficient subjects. Vitamin K prophylaxis in the newborn babies by 2 mg oral route would be benefit and can be applied routinely as well as 1 mg parenteral route to prevent both HDN and APCD syndrome particularly in breast fed infants. The routine practice of giving vitamin K1 prophylaxis 2 mg orally or 0.5-1 mg intramuscularly should be recommended to all newborn infants. Giving VKP by oral route is practical for developing countries because of simple way of administration, low cost, low toxicity, as well as high efficacy.
本文评估了口服不同剂量维生素K(VKP)对新生儿的影响,并与出生时单次剂量的标准肠外给药途径进行了比较。236名健康的母乳喂养婴儿被分为4组,在出生后2至4小时内分别接受1毫克维生素K1肌肉注射,以及2毫克、3毫克、5毫克口服维生素K1。在2周龄和4至6周龄时通过凝血酶试验测量维生素K依赖的凝血因子。结果显示,这4组在凝血酶原复合物平均水平和凝血酶原复合物缺乏受试者数量方面没有统计学差异。通过口服2毫克途径对新生儿进行维生素K预防是有益的,并且可以像1毫克肠外途径一样常规应用,以预防新生儿出血症(HDN)和获得性凝血因子缺乏综合征(APCD),特别是在母乳喂养的婴儿中。建议对所有新生儿常规给予2毫克口服或0.5至1毫克肌肉注射维生素K1进行预防。由于给药方式简单、成本低、毒性低以及疗效高,口服维生素K预防对于发展中国家来说是切实可行的。